Theravance biopharma announces ampreloxetine presentations at the international msa congress

Dublin , may 9, 2025 /prnewswire/ -- theravance biopharma, inc. ("theravance biopharma" or the "company") (nasdaq: tbph) today announced presentation of analyses of its previous phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (noh) at the international msa congress, taking place may 9-11 in boston, massachusetts. a subgroup analysis selected as a platform presentation focused on patients with multiple system atrophy (msa) in the redwood 0170 study (nct03829657), an international phase 3, placebo-controlled, double-blind, randomized withdrawal trial, designed to demonstrate clinical worsening in those assigned to placebo.
MSA Ratings Summary
MSA Quant Ranking